These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 24671837

  • 1. [From hyponatremia to tolvaptan].
    Cernaro V, Santoro D, Lacquaniti A, Montalto G, Buemi M.
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671837
    [Abstract] [Full Text] [Related]

  • 2. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
    Tuli G, Tessaris D, Einaudi S, De Sanctis L, Matarazzo P.
    J Clin Res Pediatr Endocrinol; 2017 Sep 01; 9(3):288-292. PubMed ID: 28515029
    [Abstract] [Full Text] [Related]

  • 3. [Etiology, diagnostics and therapy of hyponatremias].
    Laczi F.
    Orv Hetil; 2008 Jul 20; 149(29):1347-54. PubMed ID: 18617466
    [Abstract] [Full Text] [Related]

  • 4. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP, DeVita MV, Michelis MF.
    Int Urol Nephrol; 2012 Jun 20; 44(3):865-71. PubMed ID: 21607553
    [Abstract] [Full Text] [Related]

  • 5. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A.
    J Clin Endocrinol Metab; 2013 Apr 20; 98(4):1321-32. PubMed ID: 23401044
    [Abstract] [Full Text] [Related]

  • 6. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ, Ahmad F, Blais JD, Chiodo J, Zhou W, Glaser LA, Czerwiec FS.
    Cancer Med; 2017 Apr 20; 6(4):723-729. PubMed ID: 28251822
    [Abstract] [Full Text] [Related]

  • 7. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH, Bohm NM, Nemecek BD, Crawford R, Kelley D, Bhasin B, Nietert PJ, Velez JCQ.
    Am J Kidney Dis; 2018 Jun 20; 71(6):772-782. PubMed ID: 29478867
    [Abstract] [Full Text] [Related]

  • 8. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S.
    Hosp Pract (1995); 2017 Aug 20; 45(3):111-117. PubMed ID: 28449624
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N.
    J Clin Endocrinol Metab; 2006 Jun 20; 91(6):2145-52. PubMed ID: 16522696
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia.
    Lee MY, Kang HJ, Park SY, Kim HL, Han E, Lee EK.
    Clin Ther; 2014 Sep 01; 36(9):1183-94. PubMed ID: 25151571
    [Abstract] [Full Text] [Related]

  • 11. [Hyponatremia : The water-intolerant patient].
    Hensen J.
    Med Klin Intensivmed Notfmed; 2012 Sep 01; 107(6):440-7. PubMed ID: 22911166
    [Abstract] [Full Text] [Related]

  • 12. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
    Estilo A, McCormick L, Rahman M.
    Adv Ther; 2021 Dec 01; 38(12):5721-5736. PubMed ID: 34693505
    [Abstract] [Full Text] [Related]

  • 13. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
    Gargani L, Schmidt PH, Gheorghiade M.
    Expert Rev Cardiovasc Ther; 2011 Dec 01; 9(12):1505-13. PubMed ID: 22103869
    [Abstract] [Full Text] [Related]

  • 14. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
    Wada K, Matsukawa U, Fujimori A, Arai Y, Sudoh K, Sasamata M, Miyata K.
    Biol Pharm Bull; 2007 Jan 01; 30(1):91-5. PubMed ID: 17202666
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C, Robinson P, O'Reilly K, Lundberg J, Gisby M, Ländin M, Skov J, Trueman D.
    BMC Endocr Disord; 2016 May 16; 16(1):22. PubMed ID: 27184496
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of hyponatremia: new developments and controversies].
    Hensen J.
    Dtsch Med Wochenschr; 2011 Apr 16; 136(17):904-9. PubMed ID: 21523644
    [Abstract] [Full Text] [Related]

  • 17. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).
    Verbalis JG, Ellison H, Hobart M, Krasa H, Ouyang J, Czerwiec FS, Investigation of the Neurocognitive Impact of Sodium Improvement in Geriatric Hyponatremia: Efficacy and Safety of Tolvaptan (INSIGHT) Investigators.
    Am J Kidney Dis; 2016 Jun 16; 67(6):893-901. PubMed ID: 26874645
    [Abstract] [Full Text] [Related]

  • 18. Treatment of hyponatremia induced by the syndrome of Inappropriate antidiuretic hormone secretion: a multidisciplinary spanish algorithm.
    Runkle I, Villabona C, Navarro A, Pose A, Formiga F, Tejedor A, Poch E.
    Nefrologia; 2014 Jun 16; 34(4):439-50. PubMed ID: 25036057
    [Abstract] [Full Text] [Related]

  • 19. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 16; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 20. [Current options of treatment of hyponatremia].
    Tesař V.
    Vnitr Lek; 2016 Dec 16; 62 Suppl 6():97-101. PubMed ID: 28124939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.